Business Context and Reporting Period
Company: Alphatec Holdings, Inc. (ATEC)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Industry: Medical Technology (Spine Surgery)
Overview: Alphatec is a medical technology company focused on the design and development of technology for the surgical treatment of spine disorders. The company operates through wholly-owned subsidiaries Alphatec Spine, SafeOp Surgical, and EOS imaging. Its strategy centers on creating "clinical distinction" through integrated procedural platforms (e.g., Prone TransPsoas, EOS Insight) to improve surgical predictability and outcomes.
Key Financial Metrics
| Metric (in thousands) | 2025 | 2024 |
|---|---|---|
| Total Revenue | $764,155 | $611,562 |
| Gross Profit | $531,888 | $424,262 |
| Gross Margin | 69.6% | 69.4% |
| Operating Loss | $(82,128) | $(136,169) |
| Net Loss | $(143,358) | $(162,123) |
| Diluted Net Loss Per Share | $(0.96) | $(1.13) |
| Cash and Cash Equivalents (Year End) | $160,806 | $138,840 |
| Operating Cash Flow | $45,231 | $(44,651) |
| Total Debt (Principal) | $691,667 | $589,518 |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased by $152.6 million (25%) to $764.2 million, driven by a 22% increase in surgical volume and a 4% increase in average revenue per surgery. Surgeon user base grew by 20%.
- Profitability Improvement: Operating loss narrowed significantly by $54.0 million (40%) to $82.1 million, despite higher operating expenses, due to strong gross profit expansion.
- Expense Volatility:
- Litigation Expenses: Increased by $14.0 million (143%) to $23.8 million, primarily due to a litigation settlement and ongoing matters.
- SG&A Expenses: Increased by $48.3 million (11%) to $498.5 million due to higher compensation costs and investment in the sales channel.
- R&D Expenses: Decreased by $4.5 million (6%) to $76.3 million, largely due to a reduction in stock-based compensation related to development service agreements.
- Debt Restructuring: The company issued $405.0 million in 0.75% Convertible Senior Notes due 2030 and used proceeds to repurchase 80% of its 2026 Notes, resulting in a $17.6 million loss on debt extinguishment.
- Cash Flow Turnaround: Operating activities provided $45.2 million in cash in 2025, a reversal from a $44.7 million outflow in 2024.
Guidance, Outlook, and Risks
Management Commentary & Outlook:
- Management expects continued growth fueled by surgeon adoption of approach-specific procedures and the expansion of the InformatiX (IX) platform.
- The company is in the nascent stages of building a profitable international footprint in Australia, New Zealand, and Japan.
- Future capital requirements will depend on revenue growth, R&D spending, and international expansion. The company believes current liquidity is sufficient for at least 12 months.
Key Risks & Contingencies:
- Profitability: The company has a history of net losses and an accumulated deficit of $1.4 billion as of December 31, 2025. It may need to raise additional funds in the future.
- Regulatory: Products are subject to extensive FDA regulation. Delays in clearance or approval for new products could hinder commercialization.
- Supply Chain: Reliance on third-party manufacturers and a single supplier (Invibio) for PEEK raw materials poses supply disruption risks.
- Reimbursement: Sales depend on third-party payor coverage; changes in reimbursement policies could adversely affect demand.
- Legal: Ongoing litigation and potential product liability claims could result in significant costs.
Investor Verification Checklist
- Debt Covenants: Verify compliance with liquidity covenants in the Braidwell Term Loan and Revolving Credit Facility, especially given the high debt load ($691.7M principal).
- Inventory Valuation: Review the "Lower of Cost or Net Realizable Value" (LCNRV) reserve for excess and obsolete inventory, which was a critical audit matter. Charges were $13.5 million in 2025.
- Litigation Exposure: Assess the impact of the $23.8 million litigation expense and any potential future liabilities from the NuVasive lawsuit or other proceedings.
- Convertible Notes: Monitor the conversion terms of the 2030 Notes (conversion price ~$15.54) and the potential for dilution or cash outflow upon conversion.
- Operating Cash Flow Sustainability: Confirm if the positive operating cash flow of $45.2 million is sustainable given the high fixed cost structure and continued investment in sales and R&D.